Features of SARS-CоV-2-Associated Pneumonia in Patients with Multiple Myeloma
https://doi.org/10.22448/AMJ.2026.1.25-32
EDN: SXMPGD
Abstract
Objective. To study the clinical features of SARS-CоV-2-associated pneumonia in patients with multiple myeloma (MM).
Materials and methods. A retrospective study was conducted analyzing outpatient records and case histories of patients with MM complicated by SARS-CоV-2-associated pneumonia who were treated at the Irkutsk Regional Clinical Hospital (Order of the Badge of Honour) and infectious disease hospitals in 2020–2022.
Results. In 2020–2022, SARS-CоV-2-associated pneumonia ranked first in the structure of infectious complications in MM (24% of the total number of infectious episodes). Higher incidence was registered in patients with decreased normal immunoglobulin G levels < 5 g/L. Lower incidence of SARS-CoV-2 infection was noted upon achievement of MM response (remission) compared with newly diagnosed and relapsed patients (p=0.035 and p < 0.001). Predictors of fatal outcome in MM patients with COVID-19- associated pneumonia were: grade 4 lung involvement, decreased normal IgG < 5 g/L, neutropenia < 0.5×109 /L, chronic kidney disease stage 3–5, ECOG performance status 3–4, and elderly age.
Conclusion. New data have been obtained that can be used for the diagnosis and treatment of SARS-CоV-2-associated pneumonia in MM patients.
Supporting agencies: The study was not sponsored.
About the Authors
N. R. Solovkova
Irkutsk Regional Clinical Hospital (Order of the Badge of Honour)
Russian Federation
Russian Federation
Natalya R. Solovkova
Irkutsk
N. O. Saraeva
Irkutsk State Medical University
Russian Federation
Russian Federation
Natalya O. Saraeva
Irkutsk
V. V. Voytsekhovsky
Amur State Medical Academy
Russian Federation
Russian Federation
Valery V. Voytsekhovsky
Blagoveshchensk
References
1. Mendeleeva L.P., Votiakova O.M., Rekhtina I.G., et al. Multiple myeloma. Clinical recommendations. Journal of Modern Oncology. 2020; 22 (4): 6–28. DOI: https://doi.org/10.26442/18151434.2020.4.200457 (In Russ.)
2. Bessmeltsev S.S., Karyagina E.V., Ilyushkina E.Yu., et al. Clinical Efficacy of Daratumumab in Monotherapy of Relapsed/Refractory Multiple Myeloma. Clinical Oncohematology. 2020; 13 (1): 25–32. DOI: https://doi.org/10.21320/2500-2139-2020-13-1-25-32 (In Russ.)
3. Semochkin S.V. Mechanisms of action of immunomodulatory drugs — from teratogenicity to treatment of multiple myeloma. Russian Journal of Hematology and Transfusiology. 2022; 67 (2): 240–260. DOI: https://doi.org/10.35754/0234-5730-2022-67-2-240-260 (In Russ.)
4. luchinin A.S., Semochkin S.V. Very good partial remission predicts progression free survival in patients with multiple myeloma. Oncohematology. 2024; 19 (1): 51–55. DOI: https://doi.org/10.17650/1818 8346 2024 19 1 51 55 (In Russ.)
5. Hematology. National leadership. Edited by O.A. Rukavitsyn. Moscow: GEOTAR-Media, 2019. 784 p. ISBN: 978-5-9704-3327-0 (In Russ.)
6. Voytsekhovsky V.V., Landyshev Yu.S., Yesenin V.V., et al. Analysis of treatment results in patients with multiple myeloma. Far Eastern Medical Journal. 2007; 1: 47–50. (In Russ.)
7. Voytsekhovsky V.V., Landyshev Yu.S., Grigorenko A.A., et al. Multiple myeloma. Modern principles of diagnosis and treatment. Blagoveshchensk: Polysfera, 2012. 140 p. (In Russ.)
8. Management of oncohematological patients during the COVID-19 pandemic. Edited by I.V. Poddubnaya. Moscow: Economy-Inform, 2022. 140 p. (In Russ.)
9. Galanin V.V., Demko I.V., Bakhtina V.I., et al. COVID-19 infection in patients with multiple myeloma (review article). Bulletin of Medical Science. 2022; 4: 117–123. (In Russ.)
10. Cook G., Ashcroft A.J., Pratt G., et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapy. British Journal of Haematology. 2020; 190 (2): e83–e86. DOI: https://doi.org/10.1111/bjh.16874
11. Engelhardt M., Shoumariyeh K., Rösner A., et al. Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica. 2020; 105 (12): 2872–2878. DOI: https://doi.org/10.3324/haematol.2020.262758
12. Palumbo A., Ave-Loiseau H., Oliva S., et al. Revised international staging system for multiple myeloma: A report 61 from international myeloma working group. Journal of Clinical Oncology. 2015; 33 (26): 2863– 2869. DOI: https://doi.org/10.1200/JCO.2015.61.2267
13. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology. 1982; 5 (6): 649–655.
Review
For citations:
Solovkova N.R., Saraeva N.O., Voytsekhovsky V.V. Features of SARS-CоV-2-Associated Pneumonia in Patients with Multiple Myeloma. Amur Medical Journal. 2026;14(1):25-32. (In Russ.) https://doi.org/10.22448/AMJ.2026.1.25-32. EDN: SXMPGD
Views:
20
JATS XML
Email this article 